Ascendis Pharma A/S expected to post a loss of €2.38 a share - Earnings Preview

Ascendis Pharma A/S

04/11/2023 02:01

* Ascendis Pharma A/S  ASND.OQ   ASND.O  is expected to show
a
rise in quarterly revenue when it reports  results 
    * The Hellerup Denmark-based   company is expected to report
 a
214.7% increase in revenue to €48.115 million from €15.29
million a year ago, according to the mean estimate from 8
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Ascendis Pharma A/S
is
for a loss of €2.38 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ascendis
Pharma
A/S is $146​, above​ its last closing price of $94.65. ​​​

Previous quarterly performance (using preferred earnings measure
in euros). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -2.57       -2.59      -2.16     Beat    16.6
 Mar. 31 2023  -2.65       -2.66      -1.98     Beat    25.6
 Dec. 31 2022  -2.44       -2.56      -3.70     Missed  -44.5​
 Sep. 30 2022  -2.49       -2.49      -3.03     Missed  -21.7
 ​​Jun.        -2.08       -2.13      -1.46     Beat    31.5
 30 2022                                                
 Mar. 31 2022  -1.98       -2.00      -2.21     Missed  -10.5​
 Dec. 31 2021  -2.39       -2.34      -1.87     Beat    20.2
 Sep. 30 2021  -2.30       -2.29      -1.47     Beat    35.9
 This summary was machine generated November 4 at 02:01 GMT.  All
figures in euros  unless otherwise stated